Manufactured by MerLion Pharmaceuticals GmbHbased in GERMANY
Finafloxacin shows remarkable activity against a number of the highly dangerous category A and B biological agents, as classified by the Centers for Disease Control and Prevention (CDC), especially Burkholderia pseudomallei, Burkholderia mallei, Francisella tularensis, Coxiella burnetii and Yersinia pestis. MerLion is collaborating with the UK Defence Science and Technology Laboratory (Dstl) - ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you